Investors & News

Investor Relations

Ascendis Pharma is a clinical stage biopharmaceutical company applying its TransCon technology to develop a pipeline of long-acting prodrug therapies with best-in-class profiles to address large markets with significant unmet medical needs.

Stock Information
ASND (Common Stock)
ExchangeNASDAQ GS (US Dollar)
Change (%)0.00 (0.00%)
Data as of 09/25/17 4:00 p.m. ET
Refresh quote
Stock chart for: ASND.O.  Currently trading at $36.13 with a 52 week high of $42.00 and a 52 week low of $17.15.
Recent NewsMore >>
Ascendis Pharma A/S Announces Dosing of Subjects in Phase 1 Trial of TransCon PTH
Ascendis Pharma A/S Announces Presentations on Rare Disease Endocrinology Pipeline at Upcoming Medical Conferences
Ascendis Pharma A/S Reports Second Quarter 2017 Financial Results
Upcoming EventsMore >>
There are currently no events scheduled.
Primary IR Contact
Scott T. Smith
Chief Financial Officer
Ascendis Pharma

Data provided by Nasdaq. Minimum 15 minutes delayed.